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It is nowadays well known that accurate pathological 
staging is crucial for lung cancer patients. However, the role 
of lymphadenectomy seems to be still an open problem: 
does it exist a real benefit from it in terms of disease free 
survival (DFS) and overall survival (OS)? Should we 
perform a complete dissection of the mediastinum and 
hilum or sampling could be enough? However, there are 
also other open questions and one in particular is eliciting 
interest among thoracic surgeons and oncologists; it 
regards the topic addressed in a paper published in the 
Annals of Surgical Oncology last August by Samayoa and 
colleagues (1). 
The aim of that study was to establish whether there is 
a correlation between the numbers of lymph nodes (LN) 
removed at the time of operation and OS; they studied a 
large population of non-small cell lung cancer (NSCLC) 
patients collected in the National Cancer Data Base during 
a 10-year study period [2004–2014]. The design of the 
study was extremely simple, with a comparison of OS 
between five groups of patients with pathologically negative 
LN identified by the number of LN removed: Group 1, 1 
to 4 LN; Group 2, 5 to 8 LN; Group 3, 9 to 12 LN; Group 
4, 13 to 16 LN and Group 5, 17 or more. T4 patients were 
excluded; the surgical procedure ranged from sublobar 
resections to pneumonectomy. As the authors reported in 
their “Table 1”, the above-mentioned inclusion criteria 
progressively reduced the number of patients included in 
the study from more than 1,000,000 to 98,970; thus, less 
than 10% of the patients included in the database were 
eligible for the study, although the number is still large 
enough to allow statistical analysis.
The study showed an advantage in terms of OS for 
patients with a higher number of LN removed, with a cut-
off at 10 LN; particularly, it was observed that patients with 
9 or less LN removed had a 12% increased risk of death. 
The conclusions confirmed “a significant correlation between 
the number of LN pathologically examined and overall survival 
in NSCLC patients”. 
These results have already been reported in previous 
studies with data drawn from the Surveillance Epidemiology 
and End Results (SEER) database (2-4) and the California 
Cancer Registry (5), although the number of patients 
was smaller. In addition to the importance of the number 
of LN removed, these studies pointed out the large 
discrepancy between surgeons in the strategy to assess LN; 
they concluded that inadequate LN evaluation is “a major 
quality gap, for which corrective intervention is warranted” (4). 
It is impossible to disagree: lymphadenectomy should 
be certainly standardized. However, some details, also 
in the paper of Samayoa (1), remain controversial and 
may limit statistical significance. Before speculating on 
the potential impact of the number of LN removed on 
outcome, we should consider also other variables that are 
equally important: (I) the site of dissection (hilum and/or 
mediastinum); (II) the type of lymphadenectomy (complete 
hilar and mediastinal nodal dissection vs. sampling); and 
(III) the quality of the material removed (en bloc LN vs. 
pieces of LN). In this and in most of the previous studies, a 
pathologically N0 population of patients was included, but 
no overall information about the site of lymphadenectomy 
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was reported. This approach may favor misunderstanding: 
what variable really impacts on survival? Most of the studies 
confirm that the minimum number of LN to be resected 
is 10; however, there is a big difference in terms of impact 
on prognosis if we consider 10 negative hilar LN or 5 
negative hilar plus 5 negative mediastinal LN or 10 negative 
mediastinal LN.
The second point has been extensively considered in 
the literature; a recent paper by Darling (6) reports the 
results of the American College of Surgery Oncology 
Group Z0030 Trial and seems to definitively clarify that no 
differences can be appreciated between systematic sampling 
and extensive mediastinal nodal dissection in terms of 
DFS and OS. However, 2 years later, a review by the same 
author provided a different interpretation of that trial (7). 
In fact, since the eligibility criteria excluded clinical T3 
and T4 tumors and patients with preoperatively positive 
hilar or mediastinal LN, it could be not correct to consider 
equivalent the two procedures in patients with advanced 
disease. Wu (8) found a statistically significant difference 
in favor of nodal dissection in a cohort of patients that 
preoperatively did not receive invasive staging, supporting 
the impact of this procedure on survival. Furthermore, 
because both studies showed that there was no increased 
risk of complications due to mediastinal LN dissection, this 
procedure should be preferred. 
Regarding the third open question, it seems intuitive 
that the en bloc LN removal guarantees a better chance 
to discover micrometastases. Samayoa misses all this 
information in his paper; it could be considered a strong 
bias risking invalidating results. 
Nodal involvement certainly influences prognosis in 
NSCLC patients, but it is not the only variable involved: 
the type of resection (anatomical versus non-anatomical), 
plays also a crucial role. Furthermore, the type of surgical 
procedure is often associated with the patient’s clinical 
status: sublobar resections may be reserved to patients 
with poor functional status and these two factors together 
bear negatively on outcome, independently from the nodal 
status. This concept is completely missed in this study, 
where more than 13,000 patients (13.3%) received sublobar 
resections [12,608] or resections not otherwise specified 
[596]. Also, the extension of the resection seems related to 
the number of LN removed; in fact, in the text it is clearly 
reported that “…patients who underwent less than a lobectomy 
had a mean of 5.6 LN removed, compared with a mean of 9.2 for 
those who underwent lobectomy or bi-lobectomy, and 12.8 with 
pneumonectomy (P<0.001)”. It has been demonstrated that the 
type of parenchymal resection shows an impact on survival: 
lobectomy should be preferred and segmentectomy may be 
considered only at early stages, particularly in patients at 
increased risk; wedge resections are at increased risk of local 
recurrence. However, in this paper no information clarifies 
what does it mean “less than lobectomy”. In other words, in 
“less than lobectomy” patients what is the most important 
factor correlated with OS? The suboptimal resection or the 
reduced number of LN removed? … or both? Furthermore, 
in this study more than 3,000 patients (3.3% of population) 
had residual disease (R1); does this group belong to the “less 
than lobectomy” group? This was another confusing factor. 
Large sample numbers are not always useful to obtain a 
high statistical power! 
Notwithstanding the role of lymphadenectomy in the 
management of lung cancer is always emphasized, when 
large series or database are analyzed it is clear that in our 
daily surgical activities we act differently from the way we 
should… or what we write. This huge variability leads to a 
number of criticisms in the interpretation of data. From the 
paper of Little (9) published in 2005 few things seem to be 
changed. Probably the percentage of patients that receive 
pre- or intraoperative LN assessment is increased, but 
international guidelines are not always strictly followed (10). 
This critical point contributes to the inhomogeneity of data 
within the database, invalidating the analysis. Much more 
need to be done to reduce this variability and finally be able 
to answer the “primordial” question: what is the real role of 
lymphadenectomy: to cure or to stage? 
In conclusion, although with several limitations, the 
report from Samayoa (1) is stimulating but it requires other 
studies to be confirmed. An interesting suggestion for our 
daily surgical activities comes from Ramón Rami-Porta (11) 
in his 2013 editorial: “Leave no lymph node behind!”. In fact, 
a more accurate routine lymphadenectomy will certainly 
provide more information with a homogeneous population 
of patients, and consequent reliable data for future studies. 
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